Estradiol topical - Orion

Drug Profile

Estradiol topical - Orion

Alternative Names: Divigel; Estradiol gel - Orion; Estradiol hemihydrate; Gynpolar; Sandrena; Sisare Gel Mono

Latest Information Update: 27 Mar 2014

Price : $50

At a glance

  • Originator Orion
  • Developer Merck & Co; POLA; Vertical Pharmaceuticals
  • Class Antineoplastics; Estradiol congeners; Estrenes; Hormonal replacements; Small molecules
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Marketed Postmenopausal osteoporosis; Vasomotor symptoms

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 24 Mar 2014 Vertical Pharmaceuticals acquires estradiol topical from Upsher-Smith in USA
  • 30 Jun 2009 Final efficacy and adverse events data from a phase III trial in Vasomotor symptoms released by Upsher-Smith Laboratories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top